Literature DB >> 9323467

Increasing incidence of nosocomial Chryseobacterium indologenes infections in Taiwan.

P R Hsueh1, L J Teng, P C Yang, S W Ho, W C Hsieh, K T Luh.   

Abstract

To understand the clinical features, antimicrobial therapy, and epidemiology of Chryseobacterium indologenes infections, the medical records of 36 patients with nosocomial Chryseobacterium indologenes infections seen over a three-year period at National Taiwan University Hospital were reviewed. The 36 isolates recovered from these patients were studied by molecular typing and determination of antimicrobial susceptibility patterns. Nine patients had underlying neoplastic diseases, seven had diabetes mellitus, five had burn wounds, and four had uremia. The clinical syndrome included ten patients with intraabdominal infections, nine with wound sepsis, six with intravascular catheter-related bacteremia, and four with ventilator-associated pneumonia. Thirteen patients had monomicrobial bacteremia, and four had polymicrobial bacteremia. Nineteen patients (53%) developed infections associated with various indwelling devices. The deaths of five patients (14%) were directly attributable to infection with Chryseobacterium indologenes. All isolates recovered showed a wide range of resistance to commonly used antimicrobial agents. The random amplified polymorphic DNA (RAPD) patterns of the isolates differed from each other, indicating the absence of epidemiological relatedness among these isolates. Nosocomial infection caused by multiresistant Chryseobacterium indologenes appears to be an emerging problem in Taiwan and should be studied further.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9323467     DOI: 10.1007/BF02447918

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  23 in total

Review 1.  Infections associated with indwelling devices: concepts of pathogenesis; infections associated with intravascular devices.

Authors:  G M Dickinson; A L Bisno
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

2.  Flavobacterium indologenes bacteremia: clinical and microbiological characteristics.

Authors:  P R Hsueh; T R Hsiue; J J Wu; L J Teng; S W Ho; W C Hsieh; K T Luh
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

3.  Nonfermentative bacilli associated with man. 3. Pathogenicity and antibiotic susceptibility.

Authors:  M M Pedersen; E Marso; M J Pickett
Journal:  Am J Clin Pathol       Date:  1970-08       Impact factor: 2.493

4.  Flavobacterium group IIb bacteremia: report of a case and review of Flavobacterium infections.

Authors:  Y Siegman-Igra; D Schwartz; G Soferman; N Konforti
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

5.  Topical antimicrobial prophylaxis of nosocomial pneumonia in mechanically ventilated patients. Microbiological observations.

Authors:  M J Bonten; F H van Tiel; S van der Geest; H G Smeets; E E Stobberingh; C A Gaillard
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

6.  Indwelling arterial catheters as a source of nosocomial bacteremia. An outbreak caused by Flavobacterium Species.

Authors:  W E Stamm; J J Colella; R L Anderson; R E Dixon
Journal:  N Engl J Med       Date:  1975-05-22       Impact factor: 91.245

7.  Activity of meropenem against antibiotic-resistant or infrequently encountered gram-negative bacilli.

Authors:  J H Jorgensen; L A Maher; A W Howell
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

8.  Case of recurrent Flavimonas oryzihabitans bacteremia associated with an implanted central venous catheter (Port-A-Cath): assessment of clonality by arbitrarily primed PCR.

Authors:  B Verhasselt; G Claeys; A Elaichouni; G Verschraegen; G Laureys; M Vaneechoutte
Journal:  J Clin Microbiol       Date:  1995-11       Impact factor: 5.948

9.  Genotypic and phenotypic differentiation of Flavobacterium indologenes Yabuuchi et al 1983 from Flavobacterium gleum Holmes et al 1984.

Authors:  E Yabuuchi; Y Hashimoto; T Ezaki; Y Ido; N Takeuchi
Journal:  Microbiol Immunol       Date:  1990       Impact factor: 1.955

10.  Methods for identification of flavobacteria.

Authors:  M J Pickett
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

View more
  28 in total

1.  Chryseobacterium indologenes non-catheter-related bacteremia in a patient with a solid tumor.

Authors:  George B Christakis; Stavroula P Perlorentzou; Irene Chalkiopoulou; Athanasios Athanasiou; Nikolas J Legakis
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

2.  Severe sepsis due to Chryseobacterium indologenes in an immunocompetent adventure traveler.

Authors:  Genevieve McKew
Journal:  J Clin Microbiol       Date:  2014-08-27       Impact factor: 5.948

3.  Characterization of CIA-1, an Ambler class A extended-spectrum β-lactamase from Chryseobacterium indologenes.

Authors:  Takehisa Matsumoto; Mika Nagata; Nau Ishimine; Kenji Kawasaki; Kazuyoshi Yamauchi; Eiko Hidaka; Eriko Kasuga; Kazuki Horiuchi; Kozue Oana; Yoshiyuki Kawakami; Takayuki Honda
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

4.  Differences in Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Chryseobacterium gleum and Chryseobacterium indologenes.

Authors:  Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang; Yi-Han Huang
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

5.  Susceptibilities of Chryseobacterium indologenes and Chryseobacterium meningosepticum to cefepime and cefpirome.

Authors:  P R Hsueh; L J Teng; P C Yang; S W Ho; K T Luh
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

6.  Chryseobacterium indologenes peritonitis in peritoneal dialysis.

Authors:  Mehdi Afshar; Ehsan Nobakht; Susie Q Lew
Journal:  BMJ Case Rep       Date:  2013-05-24

7.  IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.

Authors:  Boukaré Zeba; Filomena De Luca; Alain Dubus; Michael Delmarcelle; Jacques Simporé; Odile G Nacoulma; Gian Maria Rossolini; Jean-Marie Frère; Jean-Denis Docquier
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191

8.  Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001).

Authors:  Jeffrey T Kirby; Helio S Sader; Timothy R Walsh; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

9.  Chryseobacterium indologenes pneumonia in a patient with non-Hodgkin's lymphoma.

Authors:  Hameed Aboobackar Shahul; Mohan K Manu; Aswini Kumar Mohapatra; Kiran Chawla
Journal:  BMJ Case Rep       Date:  2014-09-23

10.  Profile and multidrug resistance determinants of Chryseobacterium indologenes from seawater and marine fauna.

Authors:  Ana Maravić; Mirjana Skočibušić; Ivica Samanić; Jasna Puizina
Journal:  World J Microbiol Biotechnol       Date:  2012-11-07       Impact factor: 3.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.